Recruiting

Glycemic Variability of Combination Therapies in T2DM

ClinicalTrials.gov IDNCT07442006

PhasePHASE4

Enrollment178

SponsorJW Pharmaceutical

Age19 Years

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes Mellitus (T2DM)

About this study

Glycemic Variability of Combination Therapies in T2DM

Interventions

Drug: Empagliflozin/Metformin — 5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
Drug: Anagliptin — 100 mg, for 12 weeks (PO, BID)
Drug: Metformin — 500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
Drug: Empagliflozin/Linagliptin — 10/5 mg, for 12 weeks (PO, QD)

Primary outcomes

Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12 (Baseline to week 12)

Eligibility information

Inclusion Criteria: * Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor. Exclusion Criteria: * History of acute or chronic metabolic acidosis * Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²) * Severe hepatic impairment * History of heart failure (NYHA Class III/IV)

Study locations

The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator, Seoul, South Korea

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.